pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN
SUPERNUS PHARMACEUTICALS
SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SUPN. Primary therapeutic focus areas include Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), P
9715 Key West Ave, Rockville, Maryland 20850, US HQ
2005 Founded
828 Employees
Public company Type
SUPN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 9715 Key West Ave, Rockville, Maryland 20850, US
- Founded
- 2005
- Employees
- 828
- Programs
- 55
- Drugs
- 25
- Patents
- 68
SAGE-718
Phase 3 · small molecule · Huntington's Disease
SAGE-718 for Huntington's Disease is a Phase 3 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Internal code 718-CIH-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- SUPERNUS PHARMACEUTICALS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Huntington's Disease
- Status
- terminated
- Trials
- 2